BFRG BULLFROG AI HOLDINGS

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

GAITHERSBURG, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its CEO, Vin Singh, alongside distinguished guest, Daniel R. Weinberger, M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD), will participate in a fireside chat hosted by RedChip Companies on March 5, 2024 at 4:15 p.m. ET.

The fireside chat will delve into the early findings from BullFrog AI and LIBD’s collaboration which successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

This collaborative effort marks a pivotal moment in psychiatric research, utilizing over 2,800 brain samples to explore schizophrenia, bipolar disorder, major depressive disorder, and control groups through advanced graph analytics. For the first time, this partnership has enabled the clustering of subjects based on biological data alone, independent of their behavioral diagnoses. This innovative method has uncovered biological differences and similarities across various brain disorders and has identified potential biological subtypes within individual disorders. These findings have the potential to not only enhance our understanding of psychiatric conditions but also lay the groundwork for developing more targeted, effective treatments and open the door to prospective revenue-generating partnerships with pharmaceutical companies.

To participate in the fireside chat, please register at:

The fireside chat will include a live Q&A session. Questions can also be pre-submitted to .

About the Lieber Institute for Brain Development (LIBD)

The mission of the  is to translate the understanding of basic genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances that change the lives of affected individuals. LIBD is an independent, not-for-profit 501(c)(3) organization and a Maryland tax-exempt medical research institute. The Lieber Institute’s brain repository of more than 4,000 human brains is the largest collection of postmortem brains for the study of neuropsychiatric disorders in the world.

About BullFrog AI

BullFrog AI is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.

For more information visit BullFrog AI at:

Website:

LinkedIn:

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors

Dave Gentry

RedChip Companies, Inc.



800-733-2447

SOURCE: BullFrog AI Holdings, Inc.



EN
09/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BULLFROG AI HOLDINGS

 PRESS RELEASE

Join Bullfrog AI’s Exclusive Live Investor Webinar and Q&A Session on ...

Join Bullfrog AI’s Exclusive Live Investor Webinar and Q&A Session on April 23 GAITHERSBURG, Md., April 17, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on April 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Vin Singh, CEO of Bullfrog AI. Attendees will gain insight into Bullfrog AI’s innovativ...

 PRESS RELEASE

BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate...

BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial Eleison to leverage BullFrog Data Networks™ to enhance patient clustering and safety analysis in glufosfamide clinical trials GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmaceu...

 PRESS RELEASE

BullFrog AI to Present at Biotech Showcase and RESI JPM During JP Morg...

BullFrog AI to Present at Biotech Showcase and RESI JPM During JP Morgan Week GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its participation in the TechBio track at Biotech Showcase and RESI JPM, both taking place during the annual JP Morgan Healthcare Conference in San Francisco, January 13–16, 2025. At both Biotech Showcase and RESI...

 PRESS RELEASE

BullFrog AI Issues Letter to Stockholders

BullFrog AI Issues Letter to Stockholders GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our dri...

 PRESS RELEASE

BullFrog AI Announces Appointment of Chief Financial Officer

BullFrog AI Announces Appointment of Chief Financial Officer GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI’s former CFO, who recently lo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch